Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

Anke Stroet; Claudia Hemmelmann; Michaela Starck; Uwe Zettl; Jan Dörr; Friedemann Paul; Peter Flachenecker; Vinzenz Fleischer; Frauke Zipp; Holger Nackel; Bernd C. Kieseier; Andreas Ziegler; Ralf Gold; Andrew Chan

doi:10.1177/1756285611433318

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

Anke Stroet
, Claudia Hemmelmann
, Michaela Starck
, Uwe Zettl
, Jan Dörr
, Friedemann Paul
, Peter Flachenecker
, Vinzenz Fleischer
, Frauke Zipp
, Holger Nackel
, Bernd C. Kieseier
, Andreas Ziegler
, Ralf Gold
, Andrew Chan

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%). Conclusions: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.

Original language	English
Pages (from-to)	75-79
Number of pages	5
Journal	Therapeutic Advances in Neurological Disorders
Volume	5
Issue number	2
DOIs	https://doi.org/10.1177/1756285611433318
State	Published - Mar 2012
Externally published	Yes

Keywords

escalation therapy
leukaemia
mitoxantrone
multiple sclerosis
risk profile

Access to Document

10.1177/1756285611433318

Cite this

Stroet, A., Hemmelmann, C., Starck, M., Zettl, U., Dörr, J., Paul, F., Flachenecker, P., Fleischer, V., Zipp, F., Nackel, H., Kieseier, B. C., Ziegler, A., Gold, R., & Chan, A. (2012). Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Therapeutic Advances in Neurological Disorders, 5(2), 75-79. https://doi.org/10.1177/1756285611433318

@article{a58f37ab8ed24d71a60aa686a3a5996d,

title = "Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany",

abstract = "Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41\% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25\% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13\%). Conclusions: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.",

keywords = "escalation therapy, leukaemia, mitoxantrone, multiple sclerosis, risk profile",

author = "Anke Stroet and Claudia Hemmelmann and Michaela Starck and Uwe Zettl and Jan D{\"o}rr and Friedemann Paul and Peter Flachenecker and Vinzenz Fleischer and Frauke Zipp and Holger Nackel and Kieseier, \{Bernd C.\} and Andreas Ziegler and Ralf Gold and Andrew Chan",

note = "Funding Information: This work was supported by grants from the German Ministry for Education and Research (BMBF, {\textquoteleft}German Competence Network Multiple Sclerosis{\textquoteright} [KKNMS], CONTROL MS, 01GI0914 to RG and AC) and from the German Research Foundation (DFG Exc 257 to JD and FP). ",

year = "2012",

month = mar,

doi = "10.1177/1756285611433318",

language = "English",

volume = "5",

pages = "75--79",

journal = "Therapeutic Advances in Neurological Disorders",

issn = "1756-2856",

publisher = "SAGE Publications Ltd",

number = "2",

}

Stroet, A, Hemmelmann, C, Starck, M, Zettl, U, Dörr, J, Paul, F, Flachenecker, P, Fleischer, V, Zipp, F, Nackel, H, Kieseier, BC, Ziegler, A, Gold, R & Chan, A 2012, 'Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany', Therapeutic Advances in Neurological Disorders, vol. 5, no. 2, pp. 75-79. https://doi.org/10.1177/1756285611433318

TY - JOUR

T1 - Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

AU - Stroet, Anke

AU - Hemmelmann, Claudia

AU - Starck, Michaela

AU - Zettl, Uwe

AU - Dörr, Jan

AU - Paul, Friedemann

AU - Flachenecker, Peter

AU - Fleischer, Vinzenz

AU - Zipp, Frauke

AU - Nackel, Holger

AU - Kieseier, Bernd C.

AU - Ziegler, Andreas

AU - Gold, Ralf

AU - Chan, Andrew

N1 - Funding Information: This work was supported by grants from the German Ministry for Education and Research (BMBF, ‘German Competence Network Multiple Sclerosis’ [KKNMS], CONTROL MS, 01GI0914 to RG and AC) and from the German Research Foundation (DFG Exc 257 to JD and FP).

PY - 2012/3

Y1 - 2012/3

N2 - Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%). Conclusions: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.

AB - Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Methods and results: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%). Conclusions: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.

KW - escalation therapy

KW - leukaemia

KW - mitoxantrone

KW - multiple sclerosis

KW - risk profile

UR - https://www.scopus.com/pages/publications/84858662103

U2 - 10.1177/1756285611433318

DO - 10.1177/1756285611433318

M3 - Article

AN - SCOPUS:84858662103

SN - 1756-2856

VL - 5

SP - 75

EP - 79

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

IS - 2

ER -

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

Abstract

Keywords

Access to Document

Fingerprint

Cite this